Advertisement
Strategies & Technologies Driving Drug Discovery to Market
Subscribe to Drug Discovery & Development All
View Sample

FREE Email Newsletter

DDD Update

Daily news and top headlines for drug research professionals

Actavis Launches New Alzheimer's Disease Therapy

May 21, 2015 9:30 am | News | Comments

The drug was approved by the U.S. Food and Drug Administration (FDA) in December for the treatment of moderate to severe Alzheimer's disease in patients stabilized on memantine hydrochloride and donepezil hydrochloride. Read more...

TOPICS:

Brain Plaque Forecasts Alzheimer’s Years in Advance, Studies Confirm

May 20, 2015 1:49 pm | by Stephanie Guzowski, Editor | News | Comments

Brain plaques may appear up to 30 years prior to developing Alzheimer’s disease, according to the largest analysis to date of beta amyloid in people’s brains. Findings from two new meta-analyses  also confirm that amyloid screening, by PET scan or cerebral spinal fluid test, can help identify the best participants for clinical trials of Alzheimer’s drugs. Read more...

TOPICS:

Lakewood-Amedex: Novel Class Of Antimicrobials Kills Multidrug Resistant-Tuberculosis

May 20, 2015 12:51 pm | News | Comments

Lakewood-Amedex Inc., a leading developer of novel anti-infective pharmaceuticals, announced today that a recent series of in vitro studies conducted by Southern Research in Birmingham, Alabama, have demonstrated that its novel class of antimicrobials, named bisphosphocins, have proven effective at killing multidrug-resistant (MDR) strains.  Read more...

TOPICS:
Advertisement

FDA Approves First and Only Four-Times-A-Year Schizophrenia Treatment

May 20, 2015 12:44 pm | News | Comments

There's a new treatment option for schizophrenia – Invega Trinza (three-month paliperidone palmitate), the first and only schizophrenia medication to be administered just four times a year, providing the longest dosing interval available. Read more...

TOPICS:

Johnson & Johnson Expects Lucrative Return on Drug Pipeline

May 20, 2015 12:35 pm | by Associated Press | News | Comments

Johnson & Johnson expects a lucrative return from its pharmaceutical business, with plans to seek approval by 2019 for more than 10 new products, each with the potential to top $1 billion in annual sales. Read more...

TOPICS:

Activists Want to Void Patents on Gilead's High-Priced Hepatitis C Drug

May 20, 2015 12:15 pm | by Ryan Bushey, Associate Editor | Articles | Comments

These patents are being challenged all over the world. Read more...

TOPICS:

Promising Malaria and Dengue Vaccines Will Not Defeat Diseases

May 20, 2015 8:54 am | by Christopher J. Pace, Ph.D., GlobalData Managing Analyst, Infectious Diseases | Articles | Comments

Some industry pundits rightfully question the modest protective efficacies of CYD-TDV and RTS,S/AS01. Read more...

TOPICS:

Cancer Drugs Approved Quickly but Not to Patient's Benefit

May 20, 2015 8:46 am | by York University | News | Comments

High priced cancer drugs get rushed approvals despite poor trial methodology and little effect on the longevity of patients. Read more...

TOPICS:
Advertisement

Sanofi, Regeneron Announce Positive Phase 2 Data for Asthma Drug

May 20, 2015 8:42 am | News | Comments

Based on discussions with the U.S. Food and Drug Administration (FDA), this Phase 2b study may be considered one of two pivotal efficacy studies required for a potential dupilumab biologics license application (BLA) in asthma. Read more...  

TOPICS:

HIV Reservoirs Remain Obstacles to Cure

May 20, 2015 8:41 am | by NIAID | News | Comments

A primary research goal is to find an HIV cure that either clears the virus from an infected person’s body or enables HIV-infected individuals to suppress virus levels and replication to extremely low levels without the need for daily ART. Read more...

TOPICS:

Australian Researcher Helps with Ebola Vaccine Trials

May 20, 2015 8:41 am | by Monash University | News | Comments

An Australian researcher has helped identify the kind of human trial that is most effective for testing Ebola vaccines. Read more...

TOPICS:

New Alzheimer's Drug to Enter Clinical Trials

May 20, 2015 8:39 am | by Lancaster University | News | Comments

A new drug developed at Lancaster University that may help to prevent the early stages of Alzheimer’s disease is to enter clinical trials. Read more...

TOPICS:

E-cigarettes Aren’t Benign, Suggest Recent Studies

May 19, 2015 4:43 pm | by Drug Discovery & Development Staff | News | Comments

A slew of new studies detailed at the 2015 American Thoracic Society International Conference in Denver, Colorado this week are raising concerns about e-cigarettes (electronic cigarettes, or e-cigs). While the new “drug device” studies are generally ongoing, and so unpublished, their cumulative effect was impactful. Read more...

TOPICS:

Abcodia Raises $8M to Launch Ovarian Cancer Screening Test

May 19, 2015 1:14 pm | by Ryan Bushey, Associate Editor | Articles | Comments

The test will officially be on the market in the U.S. and U.K. later this year. Read more...

TOPICS:

HedgePath Pharmaceuticals To Receive $2.5 Million in Funding From Mayne Pharma

May 19, 2015 12:36 pm | News | Comments

HedgePath Pharmaceuticals, Inc., a clinical stage biopharmaceutical company that discovers, develops and plans to commercialize innovative therapeutics for patients with cancer, announced today that it has entered into a definitive agreement with an affiliate of Mayne Pharma Group Limited under which Mayne Pharma will invest $2.5 million in HPPI in a private common stock and warrant financing.  Read more...

TOPICS:

Pages

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading